PharmaBlock Sciences (Nanjing) Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Public

  • Employees
  • 2,593

Employees

  • Stock Symbol
  • 300725

Stock Symbol

  • Investments
  • 6

  • Share Price
  • $6.44
  • (As of Monday Closing)

PharmaBlock Sciences (Nanjing) General Information

Description

Pharma Block Sciences (Nanjing) Inc is a chemistry products and services provider through the pharmaceutical research and development process. Its core business activities include pilot plant and commercial manufacturing of key intermediates and active pharmaceutical ingredient, process development, custom synthesis and building blocks.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Number 81 Huasheng Road, Jiangbei New District
  • Nanjing, Jiangsu 210032
  • China
+86 400
Primary Industry
Specialty Chemicals
Stock Exchange
SHE
Vertical(s)
Corporate Office
  • Number 81 Huasheng Road, Jiangbei New District
  • Nanjing, Jiangsu 210032
  • China
+86 400

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

PharmaBlock Sciences (Nanjing) Stock Performance

As of 16-Nov-2026, PharmaBlock Sciences (Nanjing)’s stock price is $6.44. Its current market cap is $1.51B with 234M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.44 $6.51 $4.56 - $8.58 $1.51B 234M 21.6M $0.14

PharmaBlock Sciences (Nanjing) Financials Summary

As of 30-Sep-2026, PharmaBlock Sciences (Nanjing) has a trailing 12-month revenue of $318M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,763,570 1,174,196 1,042,105 1,189,323
Revenue 317,668 274,564 235,333 243,849
EBITDA 35,632 52,113 60,302 55,141
Net Income 32,144 25,550 30,596 27,896
Total Assets 810,770 1,049,048 676,055 720,034
Total Debt 3,779 16,104 193,697 246,682
Public Fundamental Data provided by Morningstar, Inc. disclaimer

PharmaBlock Sciences (Nanjing) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore PharmaBlock Sciences (Nanjing)‘s full profile, request access.

Request a free trial

PharmaBlock Sciences (Nanjing) Patents

PharmaBlock Sciences (Nanjing) Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2023109926-A1 Spirooxindole compound and use thereof in preparation of protease inhibitor as antiviral drug Inactive 17-Dec-2021
WO-2022242697-A1 Tyk2 selective inhibitor and use thereof Inactive 19-May-2021
WO-2022194261-A1 Pyrimidine-fused cyclic compound and use thereof in preparation of drug for treating pain and spinal cord injury Inactive 19-Mar-2021
WO-2022179584-A1 New ezh2 inhibitor and use thereof Inactive 26-Feb-2021
WO-2022121967-A1 Egfr tyrosine kinase inhibitor and uses thereof Inactive 09-Dec-2020
To view PharmaBlock Sciences (Nanjing)’s complete patent history, request access »

PharmaBlock Sciences (Nanjing) Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

PharmaBlock Sciences (Nanjing) Investments (6)

PharmaBlock Sciences (Nanjing)’s most recent deal was a Early Stage VC with Pet Medtech. The deal was made on 15-Dec-2024.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Pet Medtech 15-Dec-2024 Early Stage VC Drug Discovery
ChomiX Biotech 09-Jan-2022 Early Stage VC Discovery Tools (Healthcare)
Veiglo 17-Dec-2020 Later Stage VC Computers, Parts and Peripherals
Nanchuang Research Institute 24-Jun-2019 Joint Venture Laboratory Services (Healthcare)
Huishi 28-Sep-2018 Later Stage VC Specialty Chemicals
You’re viewing 5 of 6 investments. Get the full list »

PharmaBlock Sciences (Nanjing) ESG

Risk Overview

Risk Rating

Updated February, 28, 2025

31.24 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,999

Rank

Percentile

Pharmaceuticals

Industry

of 952

Rank

Percentile

Pharmaceuticals

Subindustry

of 438

Rank

Percentile

To view PharmaBlock Sciences (Nanjing)’s complete esg history, request access »

PharmaBlock Sciences (Nanjing) Exits (1)

PharmaBlock Sciences (Nanjing)’s most recent exit was on 06-Jul-2015 from TransThera. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
TransThera 06-Jul-2015 Completed
To view PharmaBlock Sciences (Nanjing)’s complete exits history, request access »

PharmaBlock Sciences (Nanjing) FAQs

  • When was PharmaBlock Sciences (Nanjing) founded?

    PharmaBlock Sciences (Nanjing) was founded in 2006.

  • Where is PharmaBlock Sciences (Nanjing) headquartered?

    PharmaBlock Sciences (Nanjing) is headquartered in Nanjing, China.

  • What is the size of PharmaBlock Sciences (Nanjing)?

    PharmaBlock Sciences (Nanjing) has 2,593 total employees.

  • What industry is PharmaBlock Sciences (Nanjing) in?

    PharmaBlock Sciences (Nanjing)’s primary industry is Specialty Chemicals.

  • Is PharmaBlock Sciences (Nanjing) a private or public company?

    PharmaBlock Sciences (Nanjing) is a Public company.

  • What is PharmaBlock Sciences (Nanjing)’s stock symbol?

    The ticker symbol for PharmaBlock Sciences (Nanjing) is 300725.

  • What is the current stock price of PharmaBlock Sciences (Nanjing)?

    As of 16-Nov-2026 the stock price of PharmaBlock Sciences (Nanjing) is $6.44.

  • What is the current market cap of PharmaBlock Sciences (Nanjing)?

    The current market capitalization of PharmaBlock Sciences (Nanjing) is $1.51B.

  • What is PharmaBlock Sciences (Nanjing)’s current revenue?

    The trailing twelve month revenue for PharmaBlock Sciences (Nanjing) is $318M.

  • What is PharmaBlock Sciences (Nanjing)’s annual earnings per share (EPS)?

    PharmaBlock Sciences (Nanjing)’s EPS for 12 months was $0.14.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process